This episode is part of ACC's ongoing initiative on implementing the 2026 Dyslipidemia guidelines. Join Drs. Samuel Kim and Romit Bhattacharya as they review new therapeutic developments from the guidelines during this discussion on the intersections of dyslipidemia and cardiometabolic syndrome management.  

This podcast is part of the ACC's Implementing the 2026 Dyslipidemia Guidelines: From Risk Stratification to Personalized Treatment initiative, supported by Merck & Co, and Eli Lilly and Company.